14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ARGX vs OKYO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARGX carries a Unified Composite Score of 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARGX vs OKYO. Trailing 12-month operating profitability (ARGX 31.9% vs OKYO 0.0%) and valuation multiples (ARGX 27.8x vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ARGX vs OKYO Key Questions & Quantitative Answers
As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARGX carries a Unified Composite Score of 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARGX leads the Growth & Scale pillar: ARGX posts +52.1% YoY revenue growth and +50.6% YoY earnings growth on $5.92B TTM revenue (59.8% gross margin, 31.9% operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ARGX generates $5.92B in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, ARGX deploys 27.9% of Rev ($1.65B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.
ARGX screens cheaper on headline valuation multiples. ARGX trades at 27.8x Forward P/E, 32.6x Trailing P/E, 1.28x PEG, and 10.0x EV/Revenue (32.1% EBITDA margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARGX (23.6% ROE) versus OKYO (-263.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ARGX carries 32.8% implied volatility (33rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 31% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.